Notably, targeting CAFs, such as through FAP, has been proposed to enhance immunotherapy efficacy [131]; however, developing separate CAR-T cells, one against CAFs and the other against tumor cells, can be complex and costly. This evidence concerns the gene FAP and neoplasm.